Business Description
Zai Lab Ltd
ISIN : KYG9887T1168
Share Class Description:
HKSE:09688: Ordinary SharesTotal Employee Number:
1,797Compare
Compare
Traded in other countries / regions
ZLAB.USA09688.Hong Kong1ZLB.GermanyZLAB N.Mexico Index Membership
Hong Kong Stock Connect IPO Date
2020-09-28Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.43 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.42 | |||||
Debt-to-EBITDA | -1.51 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.62 | |||||
Beneish M-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 23.2 | |||||
3-Year EBITDA Growth Rate | 31.7 | |||||
3-Year EPS without NRI Growth Rate | 23.8 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
3-Year Book Growth Rate | -15.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.03 | |||||
9-Day RSI | 80.6 | |||||
14-Day RSI | 76.31 | |||||
3-1 Month Momentum % | 0.65 | |||||
6-1 Month Momentum % | -0.9 | |||||
12-1 Month Momentum % | -44.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.13 | |||||
Quick Ratio | 1.92 | |||||
Cash Ratio | 1.44 | |||||
Days Inventory | 141.9 | |||||
Days Sales Outstanding | 65.54 | |||||
Days Payable | 228.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -2.27 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.47 | |||||
Operating Margin % | -58.27 | |||||
Net Margin % | -41.86 | |||||
EBITDA Margin % | -37.54 | |||||
FCF Margin % | -36.19 | |||||
OCF Margin % | -29.69 | |||||
ROE % | -26.61 | |||||
ROA % | -16.61 | |||||
ROIC % | -71.53 | |||||
3-Year ROIIC % | 65.49 | |||||
ROC (Joel Greenblatt) % | -99.09 | |||||
ROCE % | -24.72 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 92.65 | |||||
PS Ratio | 6.41 | |||||
PB Ratio | 4.81 | |||||
Price-to-Tangible-Book | 5.63 | |||||
EV-to-EBIT | -12.94 | |||||
EV-to-EBITDA | -14.17 | |||||
EV-to-Revenue | 5.32 | |||||
EV-to-Forward-Revenue | 3.43 | |||||
EV-to-FCF | -14.7 | |||||
Price-to-GF-Value | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 6.55 | |||||
| Price-to-Net-Cash | 19.51 | |||||
Earnings Yield (Greenblatt) % | -7.73 | |||||
FCF Yield % | -5.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zai Lab Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 3,509.441 | ||
| EPS (TTM) (HK$) | -1.406 | ||
| Beta | 1.0598 | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 48.14 | ||
| 14-Day RSI | 76.31 | ||
| 14-Day ATR (HK$) | 0.975615 | ||
| 20-Day SMA (HK$) | 16.1845 | ||
| 12-1 Month Momentum % | -44.02 | ||
| 52-Week Range (HK$) | 12.31 - 28.84 | ||
| Shares Outstanding (Mil) | 1,122.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zai Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zai Lab Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 84 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 83 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | 14.42 (-0.69%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 14.42 (-0.69%) | ||
| General meeting for 2026 | 2026-06-17 08:00 | 13.96 (+0.72%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 16.18 (-1.34%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 16.18 (-1.34%) | ||
| Guidance call for 2026 | 2026-04-20 08:30 | 18.27 (+0.61%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:00 | 14.94 (+0.47%) | ||
| Annual report for 2025 | 2026-02-26 | 14.94 (+0.47%) |
Show
Entries
Zai Lab Ltd Frequently Asked Questions
What is Zai Lab Ltd(HKSE:09688)'s stock price today?
The current price of HKSE:09688 is HK$20.10. The 52 week high of HKSE:09688 is HK$28.84 and 52 week low is HK$12.31.
When is next earnings date of Zai Lab Ltd(HKSE:09688)?
The next earnings date of Zai Lab Ltd(HKSE:09688) is 2026-11-06 Est..
Does Zai Lab Ltd(HKSE:09688) pay dividends? If so, how much?
Zai Lab Ltd(HKSE:09688) does not pay dividend.
Press Release
Articles on Zai Lab Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers